Data mining of current research status of clinical trial drug management in China by bibliometrics
10.12206/j.issn.2097-2024.202404050
- VernacularTitle:基于文献计量学对我国临床试验用药品管理研究现状的数据挖掘
- Author:
Chang XU
1
;
Xinna ZHOU
1
;
Lu QI
2
;
Yu WANG
2
;
Xinghe WANG
2
,
3
Author Information
1. a.Clinical Trial Institutions for Drugs and MedicalDevices,b.Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
2. Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
3. a.Clinical Trial Institutions for Drugs and MedicalDevices,b.Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
- Publication Type:Pharmacyadministration
- Keywords:
clinical trials;
medicines;
management;
bibliometrics;
data mining
- From:
Journal of Pharmaceutical Practice and Service
2025;43(8):404-409
- CountryChina
- Language:Chinese
-
Abstract:
Objective To clarify the current development status and research hotspots in the field of experimental drug management in China through data mining by bibliometric. Methods Key words such as “experiment”, “drug”, and “management” were used to search the Chinese literature in China National Knowledge Infrastructure （CNKI）. The title, author name, author affiliation, Chinese abstract, Chinese keywords, publication period, journal name, and other content of the literature were extracted from the literature. Cluster analysis was performed by CNKI literature visualization analysis system, CiteSpace and other software, and a network knowledge map was drawn. Results The literature in the field of experimental drug management in China was first published in 1994, and a total of 140 articles were published until 2022. Among them, 20 articles were supported by relevant funds, and the keyword co-occurrence frequency was highest among “subjects”. The most frequently published medium was the Chinese Pharmacological Yearbook. Conclusion At present, the quantity and quality of literature in the field of experimental drug management in China were relatively small, and the cooperation and communication among authors were not close. The funding from various fund projects in this field was also lacking. These factors led to a lower overall development level and slower development speed in this field.
